Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

被引：3

作者：

Iskierka-Jazdzewska, Elzbieta ^{[1
]}

Kim, Won Seog ^{[2
]}

Cho, Seok-Goo ^{[3
]}

Kim, Tae Min ^{[4
]}

Jarque, Isidro ^{[5
]}

Robak, Tadeusz ^{[6
]}

Poon, Michelle ^{[7
]}

Prince, H. Miles ^{[8
,9
]}

Yong, Sung ^{[10
]}

Lim, Francesca ^{[11
]}

Carpio, Cecilia ^{[12
]}

Tan, Tran-Der ^{[13
]}

Ayyappan, Sabarish ^{[14
]}

Gutierrez, Antonio ^{[15
]}

Zhang, Huilai ^{[16
]}

Cao, Junning ^{[17
,18
]}

Zhang, Mingzhi ^{[19
,20
]}

Tessoulin, Benoit ^{[21
,22
]}

Li, Jingjin ^{[23
]}

Ivanescu, Cristina ^{[24
]}

机构：

[1] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[2] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[5] Hosp Univ La Fe, Valencia, Spain

[6] Med Univ Lodz, Lodz, Poland

[7] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore

[8] Epworth Healthcare, Melbourne, Vic, Australia

[9] Univ Melbourne, Melbourne, Vic, Australia

[10] Dong A Univ Hosp, Busan, South Korea

[11] Singapore Gen Hosp, Singapore, Singapore

[12] Vall DHebron Hosp, Barcelona, Spain

[13] Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan

[14] Univ Iowa Hosp & Clin, Iowa City, IA USA

[15] Hosp Univ Son Espases, IdISBa Palma, Palma de Mallorca, Spain

[16] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China

[17] Fudan Univ, Dept Lymphoma, Shanghai Canc Ctr, Shanghai, Peoples R China

[18] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[19] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[20] Lymphoma Diag & Treatment Ctr Henan Prov, Zhengzhou, Peoples R China

[21] Nantes Univ, Sch Med, Nantes, France

[22] Univ Hosp Nantes, Nantes, France

[23] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[24] IQVIA, Amsterdam, Netherlands

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180743

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[21] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Crombie, Jennifer L.
Kim, Austin I.
Bartlett, Nancy L.
Redd, Robert A.
Patterson, Victoria
Carey, Celeste
Balasubramanian, Sobana
Odejide, Oreofe O.
Merryman, Reid W.
LaCasce, Ann
Jacobson, Caron A.
Jacobsen, Eric
Parry, Erin M.
Fisher, David C.
Herrera, Alex F.
Davids, Matthew S.
Shipp, Margaret A.
Armand, Philippe
Shouse, Geoffrey P.
BLOOD, 2023, 142
[22] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Ren, Liangliang
Li, Ling
Zhang, Lei
Li, Xin
Fu, Xiaorui
Wang, Xinhua
Wu, Jingjing
Sun, Zhenchang
Feng, Xiaoyan
Chang, Yu
Zhou, Zhiyuan
Nan, Feifei
Yan, Jiaqin
Kong, Fei
Zhang, Mingzhi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 42 - 50
[23] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Liangliang Ren
Ling Li
Lei Zhang
Xin Li
Xiaorui Fu
Xinhua Wang
Jingjing Wu
Zhenchang Sun
Xiaoyan Feng
Yu Chang
Zhiyuan Zhou
Feifei Nan
Jiaqin Yan
Fei Kong
Mingzhi Zhang
Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 42 - 50
[24] A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Collins, Graham P.
Toby, Eyre A.
Hatton, Chris S.
Radford, John
Linton, Kim M.
BLOOD, 2014, 124 (21)
[25] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Kato, Koji
Makita, Shinichi
Goto, Hideki
Kanda, Junya
Fujii, Nobuharu
Shimada, Kazuyuki
Akashi, Koichi
Izutsu, Koji
Teshima, Takanori
Fukuda, Natsuko
Sumitani, Tokuhito
Sumi, Hiroyuki
Shimizu, Shinji
Kakurai, Yasuyuki
Yoshikawa, Kenji
Tobinai, Kensei
Usui, Noriko
Hatake, Kiyohiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
[26] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Koji Kato
Shinichi Makita
Hideki Goto
Junya Kanda
Nobuharu Fujii
Kazuyuki Shimada
Koichi Akashi
Koji Izutsu
Takanori Teshima
Natsuko Fukuda
Tokuhito Sumitani
Hiroyuki Sumi
Shinji Shimizu
Yasuyuki Kakurai
Kenji Yoshikawa
Kensei Tobinai
Noriko Usui
Kiyohiko Hatake
International Journal of Clinical Oncology, 2022, 27 : 213 - 223
[27] Circulating Tumor DNA Analysis Associates with Progression- Free Survival ( PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/ R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study
Arnason, Jon E.
Brouwer-Visser, Jurriaan
Luminari, Stefano
Tucker, David
Kim, Tae Min
Kim, Won Seog
Magnano, Laura
Sun, Dylan
Cai, Jessica
Cygan, Kamil
Ambati, Srikanth
Mohamed, Hesham
Chaudhry, Aafia
Jankovic, Vladimir
BLOOD, 2023, 142
[28] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
Zinzani, Pier Luigi
Pellegrini, Cinzia
Gandolfi, Letizia
Stefoni, Vittorio
Quirini, Federica
Derenzini, Enrico
Broccoli, Alessandro
Argnani, Lisa
Pileri, Stefano
Baccarani, Michele
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
[29] Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma
Izutsu, Koji
Kumode, Takahiro
Yuda, Junichiro
Nagai, Hirokazu
Mishima, Yuko
Suehiro, Youko
Yamamoto, Kazuhito
Fujisaki, Tomoaki
Ishitsuka, Kenji
Ishizawa, Kenichi
Ikezoe, Takayuki
Nishikori, Momoko
Akahane, Daigo
Fujita, Jiro
Dinh, Minh
Soong, David
Noguchi, Hidehisa
Buchbjerg, Jeppe Klint
Favaro, Elena
Fukuhara, Noriko
CANCER SCIENCE, 2023, 114 (12) : 4643 - 4653
[30] Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma
Galanina, Natalie
Jasielec, Jagoda
Peace, David
Smith, Sonali M.
Nabhan, Chadi
LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 752 - 753

← 1 2 3 4 5 →